CAR T cells for lupus
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Heart & circulation, Immune system & allergy, Kidney & urinary, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 90 years old.
- You must have a confirmed diagnosis of systemic lupus erythematosus (SLE) with moderate to high disease activity.
- Your blood counts (hemoglobin, white blood cells, neutrophils, platelets) must be at certain minimum levels.
- Your liver and kidney function must be within acceptable limits.
- You must not have severe lupus nephritis (kidney damage) requiring dialysis.
- You must not have serious infections, HIV, hepatitis B or C, or syphilis.
- You must not have received certain previous therapies (like other CAR T cells targeting CD19 or BCMA).
- You must not be pregnant or plan to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell therapy (CAR-T cells targeting CD19 and BCMA) for people with lupus nephritis, systemic sclerosis, or Sjögren's-related lung blood vessel disease that hasn't improved with usual treatments. The goal is to see if this one-time cell infusion can calm the overactive immune system and improve symptoms.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
This trial tests a type of immune cell therapy called CAR T-cells that target CD19, for people with severe autoimmune diseases that haven't improved with standard treatments. The goal is to see if it can help calm the immune system and reduce disease activity.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.